Inactive

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, Streamlined Procedures for Evaluation and Sol... This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, Streamlined Procedures for Evaluation and Solicitation for Commercial Items, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation document will not be issued. This solicitation is issued as an RFQ. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2022-04 (eff. 01/30/2022). The Network Contracting Office (NCO) 6 Regional Procurement Office (RPO) EAST intends to award a unrestricted firm-fixed price contract for consumables for diagnostic of antinuclear antibody testing. The associated North American Industrial Classification System (NAICS) code for this procurement is 621511, Medical Laboratories, business size 35Mil. Statement of Work A procurement of consumables for the diagnosis of autoimmune disease at Hunter Holmes McGuire VA Medical Center utilizing antinuclear antibody detection by Indirect Fluorescent Antibody (IFA) slide method compatible with VA owned on-site instrumentation. This is a base plus 4 option years. Base year: Fuorescent IgG ANA-Ro Test System Qty 10 Price Extended Price Option 1: Fuorescent IgG ANA-Ro Test System Qty 10 Price Extended Price Option 2: Fuorescent IgG ANA-Ro Test System Qty 10 Price Extended Price Option 3: Fuorescent IgG ANA-Ro Test System Qty 10 Price Extended Price Option 4: Fuorescent IgG ANA-Ro Test System Qty 10 Price Extended Price BACKGROUND The Pathology and Laboratory Medicine Service at VAMC Richmond is responsible for Antinuclear Antibody testing. The antinuclear antibody (ANA) test is used as a primary test to help evaluate a person for autoimmune disorders that affect many tissues and organs throughout the body (systemic) and is most often used as one of the tests to help diagnose systemic lupus erythematosus (SLE). ANA are a group of autoantibodies produced by a person's immune system when it fails to adequately distinguish between "self" and "nonself." They target substances found in the nucleus of a cell and cause organ and tissue damage. Depending on a person's signs and symptoms and the suspected disorder, ANA testing may be used along with or followed by other autoantibody tests. Some of these tests are considered subsets of the general ANA test and detect the presence of autoantibodies that target specific substances within cell nuclei, including anti-dsDNA, anti-centromere, anti-nucleolar, anti-histone and anti-RNA antibodies. An ENA panel may also be used in follow up to an ANA. These supplemental tests are used in conjunction with a person's clinical history to help diagnose or rule out other autoimmune disorders, such as Sjögren syndrome, polymyositis and scleroderma. Different laboratories may use different test methods to detect ANA. Two common methods include immunoassay and indirect fluorescent antibody (IFA). IFA is considered the gold standard. Some laboratories will use immunoassay to screen for ANA and use IFA to confirm positive or equivocal results. Indirect fluorescent antibody (IFA) this is a method in which a person's blood sample is mixed with cells that are affixed to a slide. Autoantibodies that may be present in the blood react with the cells. The slide is treated with a fluorescent antibody reagent and examined under a microscope. The presence (or absence) and pattern of fluorescence is noted. Immunoassays--these methods are usually performed on automated instrumentation but may be less sensitive than IFA in detecting ANA. Other laboratory tests associated with the presence of inflammation, such as erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) may also be used to evaluate a person for SLE or other autoimmune disease. PERFORMANCE PERIOD The period of performance is a base plus 4 option year, tentatively starting October 01, 2022. GENERAL REQUIREMENTS Deliverables shall consist of: Fluorescent IgG ANA-Ro Test System to be processed on existing equipment (AFT3000 Automated Sample Processor and Image Navigator) with increased sensitivity to SSA/Ro autoantibodies approved by the FDA. Delivery and install address: Richmond VA Medical Center, 1201 Broad Rock Blvd., Richmond, VA 23249 FOB Point: Destination IAW FAR 52.252-1/52.252-2 and VAAR 852.1, the following Federal Acquisition Regulation (FAR) and Veterans Affairs Acquisition Regulation (VAAR) clauses and provisions are applicable to this acquisition and are available for view at: https://www.acquisition.gov/content/regulations The following solicitation provision apply to this acquisition: 52.212-1 Instructions to Offerors- Commercial Items (JUN 2021) Addendum to 52.212-1 Instructions to Offerors-Commercial Items (JUN 2020) 52.204-7 System for Award Management (OCT 2018) 52.204-16 Commercial and Government Entity Code Reporting (AUG 2020) 52.204-24 Representation Regarding Certain Telecom and Video surveillance Services or Equipment (NOV 2021) 52.212-2 Evaluation-Commercial Items (NOV 2021) (a) VA will compare quotes and select the product/service that represents the best benefit to the Government to fulfill the requirement based on the judgment of the contracting officer and VA users.  (a) The Government will award a contract resulting from this solicitation to the responsible Offeror whose offer conforming to the solicitation and will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Price, delivery, and completeness of spreadsheet submission. 52.212-3 Offeror Representations and Certifications Commercial Items (NOV 2021) Offerors must complete annual representations and certifications electronically via the System for Award Management (SAM) website located at https://www.sam.gov/portal in accordance with FAR 52.212-3, Offerors Representations and Certifications Commercial Items. If paragraph (j) of the provision is applicable, a written submission is required. (End of Provision) The following contract clauses apply to this acquisition: FAR 52.212-4, Contract Terms and Conditions Commercial Items (NOV 2021) applies to this acquisition. Addendum to FAR clause 52.212-4, Contract Terms and Conditions Commercial Items (Jan 2017): FAR 52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders (JUL 2021 DEVIATION) The following subparagraphs of FAR 52.212-5 are applicable: 52.204-13 System for Award Management (OCT 2018) 52.204-18 Commercial and Government Entity Code Maintenance (AUG 2020) 52.216-18 Ordering (AUG 2020) (date of award through September 30, 2018) 52.216-19 Order Limitations (Oct 1995) ($250.00 | 60 | 90 | 30 days) 52.216-20 Definite Quantity (OCT 1995) 52.216-21 Requirements (Oct 1995) (September 30, 2018) 52.216-22 Indefinite Quantity (OCT 1995) 52.217-8 Option to Extend Services (Nov 1999) 52.217-9 Option to Extend the Term of the Contract (MAR 2000) 52.222-19 Child Labor Cooperation with Authorities and Remedies (JUL 2020)) 52.223-99 Ensuring Adequate COVID-19 Safety Protocols for Federal Contractors (OCT 2021) 52.232-18 Availability of Funds (APR 1984) 52.232-33 Payment by Electronic Funds Transfer-System for Award Management (OCT 2018) 52.232-40 Providing Accelerated Payments to Small Business (NOV 2021) 852.211-72 Technical Industry Standards (NOV 2018) 852.212-70 Provisions and Clauses Applicable to VA Acquisition of Commercial Items (APR 2020) 852.203 70 Commercial Advertising. 852.232 72 Electronic Submission of Payment Requests. 852.270 1 Representatives of Contracting Officers 852.219-78 VA Notice of Limitations on Subcontracting Certificate of Compliance for Supplies and Products (SEP 2021) (DEVIATION) 852.242-71 Administrative Contracting Officer (OCT 2020) 852.247-73 Packing for Domestic Shipment (OCT 2018) BASIS FOR AWARD: Award will be based upon a comparative evaluation of quotes in accordance with the Simplified Acquisition Procedures of FAR 13. Comparative evaluation is the side by side pairwise comparison of quotes based on factors resulting in a Contracting Officer decision for the quote most favorable to the Government. All quoters shall submit the following: The best technical and price terms quote; The name, address, and telephone number of the quoter; A technical description of the item being quoted in sufficient detail to evaluate compliance with the requirements in the solicitation. This may include product literature, or other documents, if necessary; Price and any discount terms; Period for acceptance of offers. The offeror agrees to hold the prices in its offer firm for a minimum of 30 calendar days from the date specified for receipt of offers; Authorized distributor letter or other documents from the OEM or by an intermediary distributor authorized by the OEM Award will be based upon the lowest priced technically acceptable quote. To facilitate the award process, all quotes must include a statement regarding the terms and conditions herein as follows: "The terms and conditions in the solicitation are acceptable to be included in the award document without modification, deletion, or addition." OR "The terms and conditions in the solicitation are acceptable to be included in the award document with the exception, deletion, or addition of the following:" Quoters shall list exception(s) and rationale for the exception(s), if any. Submission of your response shall be received no later than 5:00pm EST on September 20, 2022. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All quotes shall be sent to the Contracting Officer Gordon Burns at gordon.burns@va.gov. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to the Contracting Officer.